Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

NCT02655016 is registered in ClinicalTrials.gov with Tesaro, Inc. as lead sponsor.

NCT NCT02655016
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02655016 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Lead sponsor
Tesaro, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 11, 2016
Completion date
May 29, 2026
Enrollment
733 (actual)
Sites
116

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian neoplasms